{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:03Z","timestamp":1791315483820,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>G12D<\/jats:sup>\n                    is one of the most prevalent and treatment-refractory mutations in colorectal cancer (CRC). The emergence of selective KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibitors offers new therapeutic opportunities, yet preclinical evidence indicates that monotherapy efficacy is constrained by signaling feedback and pathway redundancy, emphasizing the need for rational combination strategies. We systematically evaluated the biochemical, biological, and therapeutic activity of single, dual, and triple regimens combining the KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibitor MRTX1133 with cetuximab (EGFR inhibitor), alpelisib (PI3K\u03b1 inhibitor), or trametinib (MEK inhibitor) in a panel of patient-derived tumoroids and xenografts (PDXs) from metastatic CRC. MRTX1133 displayed mutation-specific activity in\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>G12D<\/jats:sup>\n                    -mutant tumoroids. Dual blockade of KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    and EGFR with MRTX1133 + cetuximab achieved near-complete inhibition of MAPK and PI3K-AKT signaling, with only marginal additional suppression upon addition of alpelisib or trametinib. In PDX models, triple combinations conferred no survival advantage over MRTX1133 + cetuximab. Likewise, dual therapy with trametinib + cetuximab was as effective as the triple regimen, suggesting functional redundancy between direct KRAS inhibition and downstream MEK blockade when EGFR is co-targeted. In non-\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>G12D<\/jats:sup>\n                    -mutant models, MRTX1133 + cetuximab modestly reduced KRAS pathway activity and slightly delayed tumor growth, consistent with a potential \u2018leakage effect\u2019. Collectively, our results identify dual KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    - EGFR inhibition as the regimen delivering maximal pathway suppression and therapeutic benefit in clinically relevant CRC models, with no clear advantage from more complex triple combinations. This work encourages prioritizing KRAS-EGFR co-targeting over multi-agent strategies that risk added toxicity, and provides a strong rationale for advancing KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibitors + cetuximab as a backbone targeted therapy in future clinical trials for\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>G12D<\/jats:sup>\n                    -mutant CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08900-0","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:16:22Z","timestamp":1779948982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of dual KRASG12D\u2013EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-6584","authenticated-orcid":false,"given":"Simonetta M.","family":"Leto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia R.","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vurchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cottino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Damico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-927X","authenticated-orcid":false,"given":"Elena","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-7608","authenticated-orcid":false,"given":"Andrea","family":"Bertotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-3365","authenticated-orcid":false,"given":"Livio","family":"Trusolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"8900_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17\u201333.","journal-title":"Cell"},{"key":"8900_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"8900_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8900_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u2013983.","journal-title":"Nat Med"},{"key":"8900_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"8900_CR6","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","volume":"40","author":"Ou","year":"2022","unstructured":"Ou, J\u00e4nne SI, Leal PA, Rybkin II TA, Sabari JK, Barve MA, et al. First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40:2530\u201338.","journal-title":"J Clin Oncol"},{"key":"8900_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120\u201331.","journal-title":"N Engl J Med"},{"key":"8900_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381.","journal-title":"N Engl J Med"},{"key":"8900_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"8900_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancer in mouse models and patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"8900_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 2020;10:1129\u201339.","journal-title":"Cancer Discov"},{"key":"8900_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRASG12D. N Engl J Med. 2023;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"8900_CR13","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRASG12C. N Engl J Med. 2023;389:2125\u201339.","journal-title":"N Engl J Med"},{"key":"8900_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 2024;14:982\u201393.","journal-title":"Cancer Discov"},{"key":"8900_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","volume":"18","author":"S Li","year":"2018","unstructured":"Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18:767\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8900_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298\u2013311.","journal-title":"Cancer Discov"},{"key":"8900_CR17","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"8900_CR18","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene. 2023;42:1620\u201333.","journal-title":"Oncogene"},{"key":"8900_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, et al. A neomorphic protein interface catalyzes covalent inhibition of RAS. Science. 2025;389:eads0239.","journal-title":"Science"},{"key":"8900_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-021-01970-2","volume":"40","author":"G Rizzo","year":"2021","unstructured":"Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res. 2021;40:178.","journal-title":"J Exp Clin Cancer Res"},{"key":"8900_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51909-2","volume":"15","author":"SM Leto","year":"2024","unstructured":"Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, et al. XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients. Nat Commun. 2024;15:7495.","journal-title":"Nat Commun"},{"key":"8900_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2012.11.007","volume":"23","author":"RB Corcoran","year":"2013","unstructured":"Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013;23:121\u20138.","journal-title":"Cancer Cell"},{"key":"8900_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"8900_CR24","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230\u20137.","journal-title":"J Clin Oncol"},{"key":"8900_CR25","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1200\/JCO.2008.21.3744","volume":"27","author":"B Jacobs","year":"2009","unstructured":"Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27:5068\u201374.","journal-title":"J Clin Oncol"},{"key":"8900_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.bjc.6606054","volume":"104","author":"JB Baker","year":"2011","unstructured":"Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer. 2011;104:488\u201395.","journal-title":"Br J Cancer"},{"key":"8900_CR27","doi-asserted-by":"crossref","unstructured":"Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci Transl Med. 2015;7:272ra12","DOI":"10.1126\/scitranslmed.3010445"},{"key":"8900_CR28","doi-asserted-by":"crossref","unstructured":"Lupo B, Sassi F, Pinnelli M, Galimi F, Zanella ER, Vurchio V, et al. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Sci Transl Med. 2020;12:eaax8313.","DOI":"10.1126\/scitranslmed.aax8313"},{"key":"8900_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1158\/1078-0432.CCR-22-2115","volume":"29","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29:1056\u201367.","journal-title":"Clin Cancer Res"},{"key":"8900_CR30","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.1158\/1078-0432.CCR-18-0717","volume":"24","author":"R Shi","year":"2018","unstructured":"Shi R, Li M, Raghavan V, Tam S, Cabanero M, Pham NA, et al. Targeting the CDK4\/6-Rb pathway enhances response to PI3K inhibition in PIK3CA-mutant lung squamous cell carcinoma. Clin Cancer Res. 2018;24:5990\u20136000.","journal-title":"Clin Cancer Res"},{"key":"8900_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer. 2021;2:271\u201383.","journal-title":"Nat Cancer"},{"key":"8900_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022;8:eabm8780.","journal-title":"Sci Adv"},{"key":"8900_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","volume":"18","author":"F Di Nicolantonio","year":"2021","unstructured":"Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, et al. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol. 2021;18:506\u201325.","journal-title":"Nat Rev Clin Oncol"},{"key":"8900_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCO.0000000000001042","volume":"36","author":"P Vanclooster","year":"2024","unstructured":"Vanclooster P, Seghers S, Prenen H. State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. 2024;36:313\u20139.","journal-title":"Curr Opin Oncol"},{"key":"8900_CR35","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123\u201333.","journal-title":"J Med Chem"},{"key":"8900_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"8900_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov. 2018;8:428\u201343.","journal-title":"Cancer Discov"},{"key":"8900_CR38","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632\u201343.","journal-title":"N Engl J Med"},{"key":"8900_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19:719\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"8900_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604\u20138.","journal-title":"Science"},{"key":"8900_CR41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/s41416-020-0776-z","volume":"122","author":"RMJM van Geel","year":"2020","unstructured":"van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1\/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. Br J Cancer. 2020;122:1166\u201374.","journal-title":"Br J Cancer"},{"key":"8900_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00280-020-04066-4","volume":"85","author":"SCFA Huijberts","year":"2020","unstructured":"Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, et al. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharm. 2020;85:917\u201330.","journal-title":"Cancer Chemother Pharm"},{"key":"8900_CR43","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-23-0592","volume":"83","author":"MA Keats","year":"2023","unstructured":"Keats MA, Han JJW, Lee YH, Lee CS, Luo J. A nonconserved histidine residue on KRAS drives paralog selectivity of the KRASG12D inhibitor MRTX1133. Cancer Res. 2023;83:2816\u201323.","journal-title":"Cancer Res"},{"key":"8900_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas M, Downward J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 2024;42:338\u201357.","journal-title":"Cancer Cell"},{"key":"8900_CR45","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606\u201320.e8.","journal-title":"Cancer Cell"},{"key":"8900_CR46","doi-asserted-by":"crossref","unstructured":"Orlen MI, Vostrejs WP, Sor R, McDevitt JC, Kemp SB, Kim IK, et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC. Cancer Discov. 2025;15:1697-716.","DOI":"10.1158\/2159-8290.CD-24-1475"},{"key":"8900_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02288-9","volume":"24","author":"DSR Bandi","year":"2025","unstructured":"Bandi DSR, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, et al. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Mol Cancer. 2025;24:76.","journal-title":"Mol Cancer"},{"key":"8900_CR48","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1007\/s10916-012-9891-6","volume":"36","author":"E Baralis","year":"2012","unstructured":"Baralis E, Bertotti A, Fiori A, Grand A. LAS: a software platform to support oncological data management. J Med Syst. 2012;36:S81\u201390.","journal-title":"J Med Syst"},{"key":"8900_CR49","unstructured":"LOEWE S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285-90."},{"key":"8900_CR50","doi-asserted-by":"crossref","unstructured":"Bliss CI The toxicity of poisons applied jointly. Annals of applied biology1939. p. p.585-615.","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"key":"8900_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"8900_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12688\/f1000research.29032.2","volume":"10","author":"F M\u00f6lder","year":"2021","unstructured":"M\u00f6lder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al. Sustainable data analysis with Snakemake. F1000Res. 2021;10:33.","journal-title":"F1000Res"},{"key":"8900_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508\u201323.","journal-title":"Cancer Discov"},{"key":"8900_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nature14969","volume":"526","author":"A Bertotti","year":"2015","unstructured":"Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526:263\u20137.","journal-title":"Nature"},{"key":"8900_CR55","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1158\/0008-5472.CAN-17-0582","volume":"77","author":"TF Meehan","year":"2017","unstructured":"Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, et al. PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Res. 2017;77:e62\u2013e6.","journal-title":"Cancer Res"},{"key":"8900_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08900-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:44:54Z","timestamp":1785105894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8900"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08900-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LT has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier, and Symphogen. The other authors declare no conflicts.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"657"}}